PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1505682-1	1992	Vanadate (V) potentiated (4- to 10-fold) the activation of cellular phospholipase A2 (PLA2) induced by H2O2 (H), a phorbol ester (T), a Ca(2+)-ionophore (A) and opsonized zymosan in macrophages.	Zymosan	171-178	phospholipase A2 group IB	Homo sapiens	68-84	
11741884-6	2002	By use of a recently described and specific inhibitor of cytosolic PLA(2)-alpha (group IV PLA(2)alpha), we show that this enzyme produces virtually all of the arachidonic acid used for the biosynthesis of leukotriene B(4) in fMLP- and opsonized zymosan-stimulated neutrophils, the major eicosanoid produced by these pro-inflammatory cells.	Zymosan	245-252	phospholipase A2 group IB	Homo sapiens	67-73	
11741884-6	2002	By use of a recently described and specific inhibitor of cytosolic PLA(2)-alpha (group IV PLA(2)alpha), we show that this enzyme produces virtually all of the arachidonic acid used for the biosynthesis of leukotriene B(4) in fMLP- and opsonized zymosan-stimulated neutrophils, the major eicosanoid produced by these pro-inflammatory cells.	Zymosan	245-252	phospholipase A2 group IB	Homo sapiens	90-101	
8938669-2	1996	Ircinin inhibited Naja naja venom, human synovial recombinant, bee venom and zymosan-injected rat air pouch PLA2 with IC50 values in the microM range, similar to those of the known inhibitor scalaradial.	Zymosan	77-84	phospholipase A2 group IB	Homo sapiens	108-112	
8034717-7	1994	This approach was complicated since initial exposure to PMA to down-regulate PKC increased cytosolic PLA2 activity which remained elevated for 16 h. In contrast, GF109203X treatment suppressed the increase in cytosolic PLA2 activity in response to zymosan and PMA but not to okadaic acid or A23187.	Zymosan	248-255	phospholipase A2 group IB	Homo sapiens	219-223	
8034717-8	1994	The results demonstrate that PMA and zymosan trigger PKC activation that leads to the activation of MAP kinase and PLA2, whereas these responses are PKC independent in okadaic acid-treated cells.	Zymosan	37-44	phospholipase A2 group IB	Homo sapiens	115-119	
8034717-9	1994	In addition, the results are consistent with a role for MAP kinase activation in regulating the activation of the 85-kDa PLA2 and arachidonic acid release in PMA-, zymosan-, and okadaic acid-stimulated cells, whereas these responses in A23187-treated cells are MAP kinase-and PKC-independent.	Zymosan	164-171	phospholipase A2 group IB	Homo sapiens	121-125	
8280102-1	1994	Phospholipase A2 (PLA2) inhibitors suppressed simultaneously, in a dose-dependent manner, the activation of NADPH oxidase and the release of 3H-labelled arachidonic acid ([3H]AA) stimulated by either phorbol 12-myristate 13-acetate (PMA) or opsonized zymosan (OZ) in human neutrophils.	Zymosan	251-258	phospholipase A2 group IB	Homo sapiens	0-16	
8280102-1	1994	Phospholipase A2 (PLA2) inhibitors suppressed simultaneously, in a dose-dependent manner, the activation of NADPH oxidase and the release of 3H-labelled arachidonic acid ([3H]AA) stimulated by either phorbol 12-myristate 13-acetate (PMA) or opsonized zymosan (OZ) in human neutrophils.	Zymosan	251-258	phospholipase A2 group IB	Homo sapiens	18-22	
8108369-3	1994	However, both types of PLA2 promoted opsonized zymosan-induced LTB4 production in a dose-dependent manner (from 10(-10) to 10(-8) M), whereas they had no effect on opsonized zymosan-induced LTC4 generation.	Zymosan	47-54	phospholipase A2 group IB	Homo sapiens	23-27	
1505682-1	1992	Vanadate (V) potentiated (4- to 10-fold) the activation of cellular phospholipase A2 (PLA2) induced by H2O2 (H), a phorbol ester (T), a Ca(2+)-ionophore (A) and opsonized zymosan in macrophages.	Zymosan	171-178	phospholipase A2 group IB	Homo sapiens	86-90	
2775481-3	1989	Also the zymosan-induced formation of thromboxane and prostaglandin E2 from endogenous sources which is thought to involve phospholipase A2 remains unaffected in the presence of this compound.	Zymosan	9-16	phospholipase A2 group IB	Homo sapiens	123-139	
3065613-2	1988	In the perfused liver, responses (e.g. vasoconstriction and glycogenolysis) to stimulating agents such as zymosan, platelet-activating factor and arachidonic acid, are inhibited by indomethacin and bromophenacyl bromide, inhibitors of cyclo-oxygenase and phospholipase A2, respectively.	Zymosan	106-113	phospholipase A2 group IB	Homo sapiens	255-271	
6818414-4	1982	These observations suggest that the zymosan-activated serum stimulus activates phospholipase A2 and that phospholipase A2 is inhibited by quercetin.	Zymosan	36-43	phospholipase A2 group IB	Homo sapiens	79-95	
6818414-4	1982	These observations suggest that the zymosan-activated serum stimulus activates phospholipase A2 and that phospholipase A2 is inhibited by quercetin.	Zymosan	36-43	phospholipase A2 group IB	Homo sapiens	105-121	
6783644-6	1981	Increased activities of phospholipase A2 were achieved by treatment with the bivalent cation ionophore A 23187 and with zymosan.	Zymosan	120-127	phospholipase A2 group IB	Homo sapiens	24-40	
6783644-7	1981	The effect of zymosan obtained from various sources was found to be exclusively due to contamination of tee zymosan particles with phospholipase A2 activity.	Zymosan	14-21	phospholipase A2 group IB	Homo sapiens	131-147	
6783644-7	1981	The effect of zymosan obtained from various sources was found to be exclusively due to contamination of tee zymosan particles with phospholipase A2 activity.	Zymosan	108-115	phospholipase A2 group IB	Homo sapiens	131-147